PharmenaWAR:PHR -0.31%57 Operating Margin % is -131.12% as of Mar. 2026. GuruFocus rates WAR:PHR with a GF Score™ of 57/100 and a GF Value™ of zł5.78 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Pharmena ranks worse than 58.94% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Pharmena's Operating Income for the
three
months ended in Mar. 2026 was zł-0.55 Mil. Pharmena's Revenue for the
three
months ended in Mar. 2026 was zł0.42 Mil. Therefore, Pharmena's Operating Margin % for the quarter that ended in Mar. 2026 was -131.12%.
Warning Sign:
Pharmena SA operating margin has been in a 5-year decline. The average rate of decline per year is -89.2%.
The historical rank and industry rank for Pharmena's Operating Margin % or its related term are showing as below:
WAR:PHR'
s Operating Margin % Range Over the Past 10 Years
Min: -1253.36 Med: -43.47 Max: 0.62
Current: -196.7
WAR:PHR's Operating Margin % is ranked worse than 58.94% of 945
companies
in the Biotechnology industry
Industry Median: -86.89
vs WAR:PHR: -196.70
Pharmena's 5-Year Average Operating Margin % Growth Rate was -89.20% per year.
Pharmena's Operating Income for the
three
months ended in Mar. 2026 was zł-0.55 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was zł-3.16 Mil.
Pharmena (WAR:PHR) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Pharmena Operating Margin % Related Terms
Pharmena Operating Margin % Historical Data
* Premium members only.
The historical data trend for Pharmena's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:PHR vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Pharmena's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmena Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmena's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Pharmena's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Pharmena's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmena (WAR:PHR) has a Operating Margin % of -131.12% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Pharmena and its competitors. According to the industry distribution chart, Pharmena ranks #557 out of 945 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Pharmena's Operating Margin % too high?
Pharmena's current Operating Margin % is -131.12%. Based on the distribution chart, Pharmena ranks #557 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmena has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmena's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmena ranks #557 out of 945 companies for Operating Margin %. This places Pharmena in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Pharmena and its competitors. Pharmena's current Operating Margin % is -131.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmena stock overvalued right now?
Based on GuruFocus' analysis, Pharmena (WAR:PHR) is currently considered Possible Value Trap. The stock's GF Value™ is zł5.78, compared to a current price of zł3.18 — trading 45% below its estimated fair value. The current Operating Margin % is -131.12%. Pharmena's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Pharmena (WAR:PHR), the current Operating Margin % is -131.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmena (WAR:PHR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmena stock appears to be undervalued.
The current stock price of zł3.18 is trading 45% below its estimated GF Value™ of zł5.78.
GuruFocus considers Pharmena to be Possible Value Trap.
Key valuation signals for WAR:PHR:
Operating Margin %: -131.12%
GF Value™: zł5.78 vs. price of zł3.18 (45% below fair value)
No single metric tells the full story. See the WAR:PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
57GF Score
Get the complete analysis for WAR:PHR
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:PHR has been successfully added to your 
